Low-dose computed tomography (LDCT) has been promoted as a screening test for lung cancer since the National Lung Cancer Screening Trial (NLST) demonstrated a 20% relative reduction in lung cancer–specific mortality compared with chest radiography (CXR) screening. In a new analysis of the trial data, in which 53 452 people at high risk were randomly assigned to receive either LDCT or CXR screening, researchers found that more than 18% of lung cancers detected by LDCT were indolent tumors, which may not have become clinically significant (Patz EF et al. JAMA Intern Med. doi:10.1001/jamainternmed.2013.12738 [published online December 9, 2013]).
Slomski A. Lung Cancers Overdiagnosed With Low-Dose CT. JAMA. 2014;311(4):349. doi:10.1001/jama.2014.62